PrognomiQ
PrognomiQ is dedicated to transforming healthcare by harnessing multi-omics data to enable early disease detection and treatment, especially for cancer. They develop innovative test products by generating extensive proprietary proteomic data and integrating it with genomic, metabolomic, and other health data to discover new approaches for early diagnosis and intervention.
Industries
Nr. of Employees
small (1-50)
PrognomiQ
1900 Alameda de las Pulgas, Suite 100, San Mateo, CA 94403
Patents
Products
Multi-omics liquid biopsy platform
An integrated laboratory and computational platform that combines deep proteomics with genomic and metabolomic measurements to support development of blood-based diagnostic tests.
Blood-based multi-omics lung cancer screening assay
A blood-based diagnostic assay combining proteomic and other molecular markers to detect early-stage lung cancer; development supported by large-scale multi-omics studies and classifier development.
Multi-omics liquid biopsy platform
An integrated laboratory and computational platform that combines deep proteomics with genomic and metabolomic measurements to support development of blood-based diagnostic tests.
Blood-based multi-omics lung cancer screening assay
A blood-based diagnostic assay combining proteomic and other molecular markers to detect early-stage lung cancer; development supported by large-scale multi-omics studies and classifier development.
Services
Discovery of candidate biomarkers using integrated proteomic, genomic and metabolomic analyses on large sample cohorts.
Automated and scalable cloud pipelines for processing large proteomics datasets and building statistical/machine-learning models.
Design and execution support for case-control studies, validation studies, and clinical assay performance evaluation.
Discovery of candidate biomarkers using integrated proteomic, genomic and metabolomic analyses on large sample cohorts.
Automated and scalable cloud pipelines for processing large proteomics datasets and building statistical/machine-learning models.
Design and execution support for case-control studies, validation studies, and clinical assay performance evaluation.
Expertise Areas
- Multi-omics biomarker discovery
- Deep plasma proteomics
- Mass spectrometry method development (ion mobility-enabled TOF, DIA/SWATH)
- Computational proteomics and cloud-based data pipelines
Key Technologies
- Untargeted deep plasma proteomics
- Ion mobility-enabled time-of-flight mass spectrometry
- Data-independent acquisition (DIA/SWATH)
- Dual-column LC-MS configurations
News & Updates
PrognomiQ announced a Series D financing of $34 million to support the development of an early detection test for lung cancer using their multi-omics platform.
PrognomiQ's recent research shows promising results in early detection of lung cancer using their deep multi-omics study.
PrognomiQ announced a Series D financing of $34 million to support the development of an early detection test for lung cancer using their multi-omics platform.
PrognomiQ's recent research shows promising results in early detection of lung cancer using their deep multi-omics study.